TY - JOUR
T1 - In Silico prediction of novel inhibitors of the DNA binding activity of FoxG1
AU - Nair, Syam Bhuvanachandran
AU - Fayaz, Shaik Mahammad Abdul
AU - Krishnamurthy, Rajanikant Golgodu
PY - 2012/11/1
Y1 - 2012/11/1
N2 - Forkhead box (Fox) proteins are a superfamily of evolutionarily conserved transcriptional regulators, which control a wide spectrum of biological processes. FoxG1 is a transcriptional repressor, whose function has been elucidated recently. FoxG1 overexpression was found to be associated with medulloblastoma and hepatoblastoma. It was suggested that the inhibition of FoxG1 could be a potential target for the development of molecular therapeutics in such type of cancers. Since, experimentally derived structure for FoxG1 is unavailable in any of the structural databases, modeling of the DNA binding domain of this protein was carried out. Potential binding sites on the protein surface were predicted. Pharmacophoric features were derived from the binding site that lies near the protein-DNA binding interface and this pharmacophore was employed for virtual screening of compounds. To the best of our knowledge, this is the first pharmacophore model proposed for screening inhibitors of FoxG1, which may interfere with its transcriptional repressor functionality. The interactions of the binding site residues with the top scoring ligand hits were analyzed. These ligands may be used for the development of potential inhibitors of FoxG1 protein.
AB - Forkhead box (Fox) proteins are a superfamily of evolutionarily conserved transcriptional regulators, which control a wide spectrum of biological processes. FoxG1 is a transcriptional repressor, whose function has been elucidated recently. FoxG1 overexpression was found to be associated with medulloblastoma and hepatoblastoma. It was suggested that the inhibition of FoxG1 could be a potential target for the development of molecular therapeutics in such type of cancers. Since, experimentally derived structure for FoxG1 is unavailable in any of the structural databases, modeling of the DNA binding domain of this protein was carried out. Potential binding sites on the protein surface were predicted. Pharmacophoric features were derived from the binding site that lies near the protein-DNA binding interface and this pharmacophore was employed for virtual screening of compounds. To the best of our knowledge, this is the first pharmacophore model proposed for screening inhibitors of FoxG1, which may interfere with its transcriptional repressor functionality. The interactions of the binding site residues with the top scoring ligand hits were analyzed. These ligands may be used for the development of potential inhibitors of FoxG1 protein.
UR - http://www.scopus.com/inward/record.url?scp=84868006449&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84868006449&partnerID=8YFLogxK
U2 - 10.2174/1573406411208061155
DO - 10.2174/1573406411208061155
M3 - Article
C2 - 22741795
AN - SCOPUS:84868006449
SN - 1573-4064
VL - 8
SP - 1155
EP - 1162
JO - Medicinal Chemistry
JF - Medicinal Chemistry
IS - 6
ER -